GO2 Foundation for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, PhD, to the role of Chief Scientific Officer. In her new position, Dr. King will be responsible for leading scientific and research priorities for a global patient advocacy group dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.
Jennifer C. King, PhD
Laurie Fenton Ambrose
“At such a critical time for our community, which faces a battle on two fronts—one against lung cancer and one against COVID-19—Jennifer King is just the person to tap for the important post of Chief Scientific Officer,” said Laurie Fenton Ambrose, President and Chief Executive Officer.
Dr. King is a cancer research scientist turned patient advocate who has the unique ability to strike a balance between understanding the impact and mechanisms of new treatments and explaining what it means to the wider cancer community. She uses her training to lead cutting-edge research initiatives to improve the lives of those living with or at risk for lung cancer.
Dr. King has been with the organization since 2015. She oversaw the development of the LungMATCH personalized medicine program for patients, which provides access to molecular testing and has increased patient enrollment in clinical trials. Dr. King formed a new research network through the Screening Centers of Excellence, including the launch of a multisite clinical trial in partnership with investigators at Memorial Sloan Kettering Cancer Center.
